読み込み中
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
前日終値
$414.87
+$7.43 · +1.82%
日中の時刻はETです。市場データは遅延する場合があります。
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
日中レンジ
現在 $414.87
52週レンジ
現在 $414.87
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
買い
バリュエーション
92
大幅な割安
センチメント
67
強気
リスク
17
低リスク
モメンタム
53
中立
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.
日中レンジ
現在 $414.87
52週レンジ
現在 $414.87
利用可能な期間全体で報告されたマージン。
売上高
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | 367.41億 USD | 334.24億 USD | 281.9億 USD | 263.23億 USD | 259.79億 USD |
| 売上原価 | 107.29億 USD | 128.58億 USD | 84.15億 USD | 64.06億 USD | 64.54億 USD |
| 粗利益 | 260.12億 USD | 205.66億 USD | 197.75億 USD | 199.17億 USD | 195.25億 USD |
| 研究開発 | 69.74億 USD | 59.64億 USD | 47.84億 USD | 44.34億 USD | 63.24億 USD |
| 販売・一般管理 | 70.5億 USD | 70.96億 USD | 61.79億 USD | 54.14億 USD | 53.68億 USD |
| 営業費用 | 153.36億 USD | 133.08億 USD | 118.42億 USD | 103.51億 USD | 118.86億 USD |
| 支払利息 | 27.55億 USD | 31.55億 USD | 28.75億 USD | 14.06億 USD | 11.97億 USD |
| 減価償却費と償却費 | 51.67億 USD | 55.92億 USD | 40.71億 USD | 34.17億 USD | 33.98億 USD |
| 営業利益 | 106.76億 USD | 72.58億 USD | 78.97億 USD | 95.66億 USD | 76.39億 USD |
| 純利益 | 77.11億 USD | 40.9億 USD | 67.17億 USD | 65.52億 USD | 58.93億 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
分割調整後の1株当たりの年間現金分配金。
$9.52
2025年（通年）+35.2% 以来 2021
2026年（一部）：$7.56
$7.04
2,021
$7.76
2,022
$8.52
2,023
$9.00
2,024
$9.52
2,025
$7.56
2,026*
* 利用可能な配当履歴のうち、暦年の一部のみを含みます。
| 種別 | 配当落ち日 | 詳細 | 基準日 | 支払日 |
|---|---|---|---|---|
配当 | 2026年8月21日 | $2.52Quarterly | 2026年8月21日 | 2026年9月11日 |
配当 | 2026年5月15日 | $2.52Quarterly | 2026年5月15日 | 2026年6月5日 |
配当 | 2026年2月13日 | $2.52Quarterly | 2026年2月13日 | 2026年3月6日 |
配当 | 2025年11月21日 | $2.38Quarterly | 2025年11月21日 | 2025年12月12日 |
配当 | 2025年8月22日 | $2.38Quarterly | 2025年8月22日 | 2025年9月12日 |
配当 | 2025年5月16日 | $2.38Quarterly | 2025年5月16日 | 2025年6月6日 |
配当落ち 2026年8月21日
$2.52
Quarterly
2026年8月21日基準 · 支払日 2026年9月11日
配当落ち 2026年5月15日
$2.52
Quarterly
2026年5月15日基準 · 支払日 2026年6月5日
配当落ち 2026年2月13日
$2.52
Quarterly
2026年2月13日基準 · 支払日 2026年3月6日
配当落ち 2025年11月21日
$2.38
Quarterly
2025年11月21日基準 · 支払日 2025年12月12日
配当落ち 2025年8月22日
$2.38
Quarterly
2025年8月22日基準 · 支払日 2025年9月12日
配当落ち 2025年5月16日
$2.38
Quarterly
2025年5月16日基準 · 支払日 2025年6月6日
この株式へのエクスポージャーを報告している上場投資信託です。
State Street SPDR S&P 500 ETF1557.T4256.95億0.33%129.35兆 JPY0.09%￥122,850+0.12%
Vanguard Morningstar Total Stock Market ETFVTI73.74億0.31%2.3兆 USD0.03%$381.94+0.63%
Vanguard S&P 500 ETFVOO61.65億0.35%1.8兆 USD0.03%$715.59+0.61%
Invesco QQQ Trust, Series 1QQQ46.79億0.92%5060.67億 USD0.18%$751.27+0.49%
Schwab U.S. Dividend Equity ETFSCHD42.53億3.86%1103.15億 USD0.06%$33.04-0.32%
iShares Core S&P 500 ETFIVV29.27億0.33%8964.4億 USD0.03%$781.97+0.60%
State Street SPDR S&P 500 ETFSPY26.89億0.33%8172億 USD0.09%$778.57+0.60%
Vanguard Morningstar Value ETFVTV22.17億0.84%2624億 USD0.03%$220.59+0.44%State Street SPDR S&P 500 ETF1557.TVanguard Morningstar Total Stock Market ETFVTIVanguard S&P 500 ETFVOOInvesco QQQ Trust, Series 1QQQSchwab U.S. Dividend Equity ETFSCHDiShares Core S&P 500 ETFIVVState Street SPDR S&P 500 ETFSPYVanguard Morningstar Value ETFVTVAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
